A Phase 2 Study to Evaluate Immune Responses of FluMist®
Completed
The primary objective of this study is to describe the level of serum antibody and cellular immune responses conferred by FluMist and TIV against influenza virus strains.
Gender:
ALL
Ages:
Between 12 months and 35 months
Trial Updated:
09/10/2021
Locations: Celia Reyes-Acuna, M.D., Corpus Christi, Texas +2 locations
Conditions: Influenza Vaccine